Amphastar Pharmaceuticals (AMPH) Gains from Sales and Divestitures (2013 - 2026)

Amphastar Pharmaceuticals' Gains from Sales and Divestitures history runs 14 years deep, the most recent figure standing at $341314.0 for Q1 2026.

• In Q1 2026, Gains from Sales and Divestitures rose 0.9% year-over-year to $341314.0; the TTM figure through Mar 2026 stood at $341314.0 (up 0.9% YoY), while the FY2025 annual figure was $372602.0, down 4.17% from the prior year.
• Gains from Sales and Divestitures was $341314.0 for Q1 2026 at Amphastar Pharmaceuticals, down from $372602.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $478068.0 in Q4 2022 to a low of $338280.0 in Q1 2025.
• Historically, Gains from Sales and Divestitures has averaged $403051.1 across 5 years, with a median of $388816.0 in 2024.
• The sharpest annual moves came in 2024 and 2026: Gains from Sales and Divestitures fell 11.73% in 2024, then grew 0.9% in 2026.
• A 5-year view of Gains from Sales and Divestitures shows it stood at $478068.0 in 2022, then fell by 7.86% to $440484.0 in 2023, then retreated by 11.73% to $388816.0 in 2024, then slipped by 4.17% to $372602.0 in 2025, then slipped by 8.4% to $341314.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $341314.0 (Q1 2026), $372602.0 (Q4 2025), and $372218.0 (Q3 2025), per Business Quant data.